You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).
This information has recently been updated and is now available.
07/20/2012 02:59 PM EDT
The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.